Blaze Bioscience Announces Poster Presentation at the American Academy of Dermatology 73rd Annual Meeting
Tumor Paint BLZ-100 results from first-in-human study in patients with skin cancer

SEATTLE, WA – March 18, 2015 – Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on March 23, 2015 in San Francisco, CA.

Dr. Miller will present results on BLZ-100 from the company’s Phase 1 study in subjects with skin cancer. The poster presentation entitled, “First in Human Phase 1 Safety Study of BLZ-100 in Subjects with Skin Cancer” will be held at E-Poster Presentation Center 1 at 12:15 p.m. PDT. E-Posters will be available at www.aad.org beginning Friday, March 20 at 7:00 a.m. PDT.

“This first-in-human study has been successful in providing key safety, dose and scheduling data on BLZ-100 which will inform our broad solid tumor program—including our ongoing Phase 1b brain cancer program underway in the U.S. and Australia,” said Blaze Bioscience President and CEO Heather Franklin. “Our goal is to demonstrate clinical proof of concept for Tumor Paint BLZ-100 in brain cancer by the end of 2015.”

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, colorectal and sarcomas.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics, and is working to develop Tumor Paint™ products and Optide-based guided cancer therapeutics. Surgery is first-line therapy for most solid tumor cancers, and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research center to discover and develop guided cancer therapeutics as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptide conjugates for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

###
Contact

Media-
Lauren Nelson
Blaze Bioscience, Inc.
(206) 535-8144
lauren.nelson@blazebioscience.com

Investor Relations-
Susan Specht Oram
SOS Communications LLC
(360) 535-3035
spechtoram@gmail.com